| Literature DB >> 35454127 |
Thomas Gabriel Schreiner1,2,3, Constantin Romanescu2,4, Bogdan Ovidiu Popescu1,5,6.
Abstract
Over the past decade, multiple sclerosis (MS), a chronic neuroinflammatory disease with severe personal and social consequences, has undergone a steady increase in incidence and prevalence rates worldwide. Despite ongoing research and the development of several novel therapies, MS pathology remains incompletely understood, and the prospect for a curative treatment continues to be unpromising in the near future. A sustained research effort, however, should contribute to a deeper understanding of underlying disease mechanisms, which will undoubtedly yield improved results in drug development. In recent years, the blood-brain barrier (BBB) has increasingly become the focus of many studies as it appears to be involved in both MS disease onset and progression. More specifically, neurovascular unit damage is believed to be involved in the critical process of CNS immune cell penetration, which subsequently favors the development of a CNS-specific immune response, leading to the classical pathological and clinical hallmarks of MS. The aim of the current narrative review is to merge the relevant evidence on the role of the BBB in MS pathology in a comprehensive and succinct manner. Firstly, the physiological structure and functions of the BBB as a component of the more complex neurovascular unit are presented. Subsequently, the authors review the specific alteration of the BBB encountered in different stages of MS, focusing on both the modifications of BBB cells in neuroinflammation and the CNS penetration of immune cells. Finally, the currently accepted theories on neurodegeneration in MS are summarized.Entities:
Keywords: blood–brain barrier; immune cells; microglia; multiple sclerosis; neurodegeneration; neuroinflammation
Mesh:
Year: 2022 PMID: 35454127 PMCID: PMC9025898 DOI: 10.3390/biom12040538
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1The cellular and most significant molecular components of the blood–brain barrier as part of the neurovascular unit (Reprinted with permission from Kadry, H., Noorani, B. and Cucullo, L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17, 69 (2020). https://doi.org/10.1186/s12987-020-00230-3) [4].
Physiological roles of the BBB and its dysfunctions in pathological conditions.
| Physiological Roles of the BBB | BBB Dysfunctions in Pathological |
|---|---|
| Maintaining of ionic metastasis | Ionic imbalance (neuronal hyperpolarization) |
| Facilitating brain nutrition | Impaired brain nutrition |
| Regulating levels of neurotransmitters | Neurotransmitter imbalance (pathologic inhibition/stimulation) |
| Limiting plasma macromolecules penetrating the brain | Macromolecule leakage |
| Protecting the brain against neurotoxins | Penetration of neurotoxins in the brain |
| Facilitating molecules elimination from the brain | Impaired residual products elimination |
Figure 2Neuroinflammation and neurodegeneration in multiple sclerosis.
Overview of alterations of the NVU components in the inflammatory state of multiple sclerosis.
| NVU Components and Other | Behavior in the Neuroinflammation Phase of MS | Most Relevant References | |
|---|---|---|---|
| Brain microvascular endothelial cells | Reduction in the expression of TJ proteins | [ | |
| Pericytes | Increased production of proinflammatory cytokines and chemokines | [ | |
| Astrocytes | Increased glutamate production | [ | |
| Oligodendrocytes/oligodendrocyte progenitor cells (OPCs) | Increased expression of inflammatory genes | [ | |
| Microglia | Activation of microglia (M1 and/or M2 phenotype) | [ | |
| Neurons | Dendritic transection | [ | |
| Immune cells | Th1 CD4 cells | Secretion of IFN-γ and TNF-α | [ |
| Th17 CD4 cells | Production of IL-17, IL-21, IL-22 | ||
| CD8 T cells | Direct cytotoxic effect | [ | |
| B cells | Antibody-dependent mechanisms (secretion of intrathecal IgG) | [ | |
| Neutrophils | Secrete pro-inflammatory cytokines (IL-1β, IL-6, IL-12, TNF-α, and IFN-γ) | [ | |
| Monocytes | Change in phenotype (CD83 +, CD209 +) | [ | |
| Mast-cells | Production of TNF-α | [ | |
Figure 3Potential mechanisms involved in neurodegenerative phases of multiple sclerosis.